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Thyroid hormone (3,5,3-triiodo-L-thyronine, T3) is an endo-
crine hormone that exerts homeostatic regulation of basal meta-
bolic rate, heart rate and contractility, fat deposition, andother phe-
nomena (1, 2). T3 binds to the thyroid hormone receptors (TRs) and
controls their regulation of transcription of target genes. The bind-
ing of TRs to thyroid hormone induces a conformational change in
TRs that regulates the composition of the transcriptional regulatory
complex. Recruitment of the correct coregulators (CoR) is impor-
tant for successful gene regulation. In principle, inhibition of the
TR-CoR interaction can have a direct influence on gene transcrip-
tion in the presence of thyroid hormones. Herein we report a high
throughput screen for small molecules capable of inhibiting TR
coactivator interactions. One class of inhibitors identified in this
screen was aromatic -aminoketones, which exhibited IC50 values
of2 M. These compounds can undergo a deamination, generat-
ing unsaturated ketones capable of reacting with nucleophilic
amino acids. Several experiments confirm the hypothesis that these
inhibitors are covalently bound to TR. Optimization of these com-
pounds produced leads that inhibited the TR-CoR interaction in
vitro with potency of0.6 M and thyroid signaling in cellular sys-
tems. These are the first small molecules irreversibly inhibiting the
coactivator binding of a nuclear receptor and suppressing its tran-
scriptional activity.
Thyroid hormone receptors (TRs)3 regulate development, growth,
and metabolism (1, 2). The TRs are nuclear receptors (NR), part of a
superfamily whose members function as hormone-activated transcrip-
tion factors (3). Themajority of thyroid hormone responses are induced
by regulation of transcription by the thyroid hormone T3 (4). Two
genes, THRA and THRB encode the two protein isoforms TR and
TR, which yield four distinct subtypes by alternative splicing (5). Sev-
eral functional domains of TRs have been identified: a ligand-indepen-
dent transactivation domain (AF-1) on the amino terminus, a central
DNA binding domain, a ligand binding domain (LBD), and a carboxyl-
terminal ligand dependent activation function (AF-2) (6). TR binds spe-
cific sequences of DNA in the 5-flanking regions of T3-responsive
genes, known as thyroid response elements,most often as a heterodimer
with the retinoid X receptor (7). Both unliganded and liganded TRs can
bind thyroid response elements and regulate genes under their control.
The unliganded TR complex can recruit a nuclear receptor corepressor
(NCoR) or a silencing mediator of retinoic acid to silence basal tran-
scription (8). In the presence of T3, TRs undergo a conformational
change with the result that the composition of the coregulator complex
can change with strong effects on transcriptional regulation. Several
coactivator proteins have been identified (9). The best studied group of
coactivators is the p160 or steroid receptor coactivator (SRC) proteins
(7) including SRC1 (10), SRC2 (11, 12), and SRC3 (13). Another group of
ligand-dependent-interacting proteins include the thyroid hormone
receptor activating protein (TRAP) (14), peroxisome proliferate-acti-
vated receptor- coactivator-1 (PGC-1) (15), and the thyroid hormone
receptor binding protein (TRBP) (16). Additionally, quantitative in vitro
binding assays (17) have shown strong interactions between TR and the
coregulators p300 (18), androgen receptor activator (ARA70) (19),
receptor interacting protein 140 (RIP140) (20), dosage-sensitive sex
reversal-adrenal hypoplasia congenital critical region of the X chromo-
some gene (DAX1) (21), and the small heterodimer partner (SHP) (22).
The coregulators mentioned have in common that they have variable
numbers of highly conserved LXXLLmotifs; termed NR-boxes, in their
nuclear receptor interacting domain (NID). The NR boxes are both
necessary and sufficient for the interaction between CoR and TR. The
coactivator binding site of TR LBD is formed by 16 residues from four
helices (H3, H4, H5, and H12) (23). Scanning surface mutagenesis
revealed that only six residues (Val284, Lys288, Ile302, Lys306, Leu454, and
Glu457) are crucial for coactivator binding (24). This feature makes the
AF-2 domain an ideal target for inhibitor development.
Several inhibitors of this interaction have been reported. The first
reported inhibitors were macrolactam-constrained SRC2 NR box pep-
tides (25). A combinatorial approach discovered novel-helical proteo-
mimetics that could selectively inhibit the interaction between coacti-
vators andTRor the estrogen receptor (ER), with selectivity between ER
isoforms ER and ER (26). A similar approach, using disulfide bridges
to constrain peptides, resulted in selective ER coactivator inhibitor
with aKd of 25 nM (27, 28). A report identifying a smallmolecule capable
of inhibiting the interaction of a NR and its coactivator was published
recently (29). These pyrimidine-based scaffolds showed affinities
between 30 and 50M but did not inhibit NR signaling in cell culture or
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in vivomodels. To date, none of these inhibitorsmay be used to regulate
NR signaling in cellular systems.
All functional TRmodulators known today are analogs of theT3 itself
(30–33). These small molecule derivatives show selectivity toward dif-
ferent isoforms of TR resulting in tissue specific activities (34). GC-1, a
TR selective agonist shows interesting properties in vivo and could be
crystallized with TR LBD (35–40). The first functional T3 antagonist
wasNH-3, which inhibits thyroid hormone function in both cell culture
and whole animal-based assays (41).
High throughput screening (HTS) together with computational
screening and fragment discovery are current methods for discovering
lead compounds for manipulation of protein function. Although such
methods have been applied to discovery of small molecule inhibitors of
protein-protein interactions (42), only a limited number of successes
have been reported (43, 44). One of the most robust and sensitive HTS
methods for studying protein-protein interactions is the competitive
fluorescence polarization assay (45). Herein, we present the first HTS
using an in vitro fluorescence polarization assay tomeasure the ability of
small molecules to inhibit the interaction between the TR LBD and its
coactivator, SRC2. This screen revealed a number of hits for inhibitors
of the TR-CoR interaction. One particular class of compounds has been
examined carefully, and its mechanism of inhibition has been investi-
gated. The resulting lead compounds are potent and selective inhibitors
of both the TR-CoR interaction in vitro and thyroid hormone signaling
in cellular systems. They have potential both as drug candidates and
useful biochemical tools for study of the role of the interaction ofTR and
its coregulators.
EXPERIMENTAL PROCEDURES
Labeled Peptides—Peptide SRC2-2 (CLKEKHKILHRLLQDSSSPV)
labeledwith 5-iodoacetamidofluorescein (Molecular Probes)was kindly
provided by JamieM. R.Moore (probe) (17);-helical proteomimetics 3
(positive control) and 11 (negative control) were kindly provided by
Timothy R. Geistlinger (26).
Vector—hTR LBD (His6 T209-D461) was cloned into the BamHI
and HindIII restriction sites downstream of the hexahistidine tag of the
expression vector pET DUET-1 (Novagen). The replacement of C309
for A in the hTR LBD construct was performed with the QuikChange
XL site-directed mutagenesis kit (Stratagene). The sequence of both
constructs was verified by DNA sequencing (Elim Biopharmaceuticals,
Inc., Hayward, CA).
Protein Expression and Purification—hTR LBD (His6; residues
T209-D461) was expressed in BL21(DE3) (Invitrogen) (10 1L culture)
at 20 °C, 0.5 mM isopropyl-1-thio-b-D-galactopyranoside added at A600
0.6 (17). When the A600 reached 4, cells were harvested, resuspended in
20 ml of buffer/1 liter of culture (20 mM Tris, 300 mM NaCl, 0.025%
Tween 20, 0.10 mM phenylmethylsulfonyl fluoride, 10 mg of lysozyme,
pH 7.5), incubated for 30 min on ice, and then sonicated for 3 3 min
on ice. The lysed cells were centrifuged at 100,000  g for 1 h, and the
supernatant was loaded onto Talon resin (20ml, Clontech). Protein was
eluted with 500 mM imidazole (3  5 ml) plus ligand (3,3,5-triiodo-L-
thyronine (Sigma)). Protein purity (90%) was assessed by SDS-PAGE
and high pressure size exclusion chromatography, and protein concen-
tration was measured by the Bradford protein assay. The protein was
dialyzed overnight against assay buffer (3  4 liters, 50 mM sodium
phosphate, 150 mM NaCl, pH 7.2, 1 mM dithiothreitol, 1 mM EDTA,
0.01%Nonidet P-40, 10% glycerol). The protein functionality was deter-
mined by a direct binding assay of SRC2-2 (see Fig. 3A) giving a Kd for
SRC2-2 of 0.44 M, agreeing with prior results. hTR LBD (His6; resi-
dues Glu148-Val410) was expressed using the same procedure as hTR
with the exception that 0.5mM isopropyl-1-thio--D-galactopyranoside
was added at A600  1.2. Unliganded protein was eluted with 100 mM
imidazole. Purity assessment and buffer exchange were carried out as
described. The functionality was determined in a direct binding assay
(see Fig. 3A) giving a Kd for SRC2-2 of 0.17 M, agreeing with prior
results. hTR LBDC309A (His6; residues Thr209-Asp461) was expressed
in BL21 cells (Stratagene) at 18–20 °C by using the pET DUET1-hTR
LBD (41). General procedures were as described above. The function-
alitywas determined in a direct binding assay (see Fig. 3A) giving aKd for
SRC2-2 of 0.17 M.
Direct Binding Assay—The protein was serially diluted from 70 to
0.002 M in binding buffer (50 mM sodium phosphate, 150 mM NaCl,
pH 7.2, 1 mM dithiothreitol, 1 mM EDTA, 0.01% Nonidet P-40, 10%
glycerol) containing 1M ligand T3 in 96-well plates (17). Then 10l of
diluted proteinwas added to 10l of labeled SRC2-2 (20 nM) in 384-well
plates yielding final protein concentrations of 35–0.001 M and 10 nM
fluorescent peptide concentration. The samples were allowed to equil-
ibrate for 30 min. Binding was then measured using fluorescence polar-
ization (excitation 485 nm, emission 530 nm) on anAnalystADplate
reader (Molecular Devices). Two independent experiments, each in
quadruplicate, were carried out for each state. Data were analyzed using
SigmaPlot 8.0 (SPSS, Chicago, Il), and the Kd values were obtained by
fitting data to the following equation (y  min  (max  min)/1 
(x/Kd)Hill slope).
Screening Procedure—The small molecule screen was carried out at
the Bay Area Screening Center (BASC) at the California Institute for
Quantitative Biology (QB3). A library comprised of 138,000 compounds
(ChemRX, 28,000; ChemDiv, 53,000; ChemBridge, 24,000; SPECS,
31,000;Microsource, 2,000) was screened in 384-well format. The com-
plete composition of this library is available from the BASC website
(ucsf.edu/basc). First, 384-well dilutions plates (costar 3702) were pre-
pared by addition of 34 l of dilution buffer (20 mM Tris-HCl, 100 mM
NaCl, pH 7.2, 1 mM dithiothreitol, 1 mM EDTA, 0.01% Nonidet P-40,
10% glycerol, 5.9% Me2SO) to each well by using a WellMate (Matrix)
followed by addition of 6 l compound solutions (1 mM compound in
dimethyl sulfoxide (Me2SO)) using a Multimek (Beckman) equipped
with a 96-channel head and mixing by subsequent aspiration and dis-
pensing. Second, 5 l from the dilution plates were transferred to 384-
well assay plates (Costar 3710) using a Multimek followed by the addi-
tion of 24l of proteinmixture (20mMTris-HCl, 100mMNaCl, pH 7.2,
1 mM dithiothreitol, 1 mM EDTA, 0.01% Nonidet P-40, 10% glycerol, 1
MTRLBD, 1MT3, 0.025M labeled SRC2-2 using aWellMate. The
final concentration of compound was 30 M with 4% Me2SO content.
Each plate was monitored by the addition of a positive control 3 and
negative control 11. After an incubation time of 2 h the binding was
measured using fluorescence polarization (excitation  485 nm, emis-
sion  530 nm) on an Analyst AD plate reader (Molecular Devices).
Additionally the fluorescence intensity was measured. All data relevant
to the project (plate and compound information, screening data, anno-
tation info, etc.) was deposited directly into amySQLdata base (v. 4.1.7).
Data weremanipulated and analyzed using protocols written in Pipeline
Pilot 4.5.1 (Scitegic, Inc). Our protocols automated the process of join-
ing experimental data to compound information, flagging suspicious
plates based on low Z-factors, extracting compounds with statistically
significant activity, and annotating hits with additional information (i.e.
chemical similarity to known bioactive compounds, known genotoxic/
cytotoxic molecules, or available compounds, and profiles from ADME
models).
Dose-response Experiments—The small molecules were serially
diluted from 1000 to 4.88 M in Me2SO into a 96-well plate (Costar
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3365). 10l of each concentrationwas transferred into 100l of binding
buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.2, 1 mM dithiothreitol, 1
mMEDTA, 0.01%Nonidet P-40, 10% glycerol) andmixed by subsequent
aspiration and dispensing. Then 10 l of diluted compound was added
to 10 l of protein mixture (20 mM Tris-HCl, 100 mM NaCl, pH 7.2, 1
mMdithiothreitol, 1mMEDTA, 0.01%Nonidet P-40, 10% glycerol, 2M
TR LBD, 2 M T3, 0.02 M labeled SRC2-2 in 384-well plates yielding
final compound concentration of 50–0.024 M. The samples were
allowed to equilibrate for 3 h. Binding was thenmeasured using fluores-
cence polarization (excitation  485 nm, emission  530 nm) on an
Analyst AD (Molecular Devices). Two independent experiments, in
quadruplicate, were carried out for each compound.Datawere analyzed
using SigmaPlot 8.0, and the Kd values were obtained by fitting data to
the following equation (ymin (maxmin)/1 (x/Kd)Hill slope).
Thyroid Hormone Competition Binding Assay—Full-length hTR
was produced using a TNT T7 quick-coupled transcription translation
system (Promega). Competition assays for binding of unlabeled T3 and
L1 were performed using 1 nM [125I]T3 in gel filtration binding assay as
described (46).
Binding Assay with L8 and L9—TR or TR C309A (5 M) and T3
(20 M) were incubated in binding buffer (100 M) with different con-
centrations L8 and L9, respectively. After 3 h at room temperature an
aliquot of 20Mwas treatedwith a denaturing buffer (10M), boiled for
2min, and separated using 10% SDS-polyacrylamide gel electrophoresis
and visualized by a fluorescence spectrometer.
Pull-down Assays—GST fusions to the thyroid hormone receptor
(full-length) were expressed in Escherichia coli BL21. Cultures were
grown to A600 1.2–1.5 at 22 °C and induced with 0.5 mM isopropyl-D-
thiogalactoside for 4 h. The cultures were centrifuged (1000  g), and
bacterial pellets were resuspended in 20 mMHepes, pH 7.9, 80 mM KCl,
6 mM MgCl2, 1 mM DTT, 1 mM ATP, 0.2 mM phenylmethylsulfonyl
fluoride, and protease inhibitors and sonicated. Debris was pelleted by
centrifugation (100,000 g). The supernatant was incubated with glu-
tathione-Sepharose 4B beads (Amersham Biosciences) and washed as
previously described. Protein preparationswere stored at20 °C in 20%
glycerol until use. [35S]methionine-labeled SRC2was produced by using
coupled in vitro transcription-translation (TNT kit, Promega). The
binding reactions were carried out on ice in a volume of 150 l com-
posed of 137.5 l of protein-binding buffer along with 10 l of GST-
bead slurry corresponding to 3 g of fusion protein, 1 l of in vitro
translated protein, and 1.5 l of ligand or vehicle. The protein-binding
buffer composed of 20 l of A-150 (20 mMHepes, 150 mM KCl, 10 mM,
MgCl2, 1% glycerol) and 2 l each of phosphate-buffered saline supple-
mented with 1% Triton X-100 and 1% Nonidet P-40. Phenylmethylsul-
fonyl fluoride, dithiothreitol, bovine serum albumin, and protease
inhibitor mixture (Novagen) was freshly prepared. The mix was incu-
bated at 4 °C with gentle agitation; the beads were pelleted, washed four
times with protein-binding buffer containing no bovine serum albumin,
and dried under vacuum for 20 min. The sample was taken up in SDS-
PAGE loading buffer and then subjected to SDS-PAGE and
autoradiography.
Transient Transfection Assays—Human bone osteosarcoma epithe-
lial cells (U2OS) cells (Cell Culture Facility, UCSF) were grown to80%
confluency in Dulbecco’s modified Eagle’s/H-21, 4.5 g/liter glucose
medium containing 10% newborn calf serum (heat-inactivated), 2 mM
glutamine, 50 units/ml penicillin, and 50 g/ml streptomycin. Cells
(1.5 106) were collected and resuspended in 0.5 ml of electropora-
tion buffer (Dulbecco’s phosphate-buffered saline containing 0.1% glu-
cose, 10 mg/ml bioprene). 5 g of a TR expression vector (full-length
hTR-CMV) and 1.5g of a reporter plasmid contained a synthetic TR
response element (DR-4) containing two copies of a direct repeat spaced
by four nucleotides (AGGTCAcaggAGGTCA) cloned immediately
upstream of aminimal (32/45) thymidine kinase promoter linked to
luciferase coding sequence (35). Cells were electroporated using a Bio-
Rad gene pulser at 350 V and 960 microfarads, pooled in growth
medium (DME H-21 with 10% charcoal-treated, hormone-stripped,
newborn bovine serum), and plated in 96-well dishes. After a 3-h incu-
bation compounds were added to the cell culture medium as Me2SO
solutions so as to yield a final Me2SO concentration of 1%. After addi-
tional 18 h of incubation, cells were harvested and assayed for luciferase
activity using the Promega dual luciferase kit (Promega) and an Analyst
AD (Molecular Devices). Data were analyzed using SigmaPlot 8.0, and
the IC valueswere obtained by fitting data to the following equation (y
min (maxmin)/1 (x/Kd)Hill slope).
RESULTS
The high-throughput screen was carried out using a 384-well plate
format. A total of 300 compounds as single points together with quad-
ruple positive and quadruple negative controls were dispensed in each
384-well plate followed by the addition of TR LBD and the labeled
SRC2-2 peptide. The SRC2-2 peptide was utilized because it had the
tightest binding (0.44 M) of all the NR box peptides investigated (17).
After incubation for 2 h the fluorescence polarization and fluorescence
intensity was measured. From the 138,000 compounds screened 27 hit
compounds inhibited the interaction between TR LBD and the
SRC2-2 coactivator peptide with at least 50% efficacy at a concentration
of 30Mand had a fluorescence intensity variation of less then 10%. The
structures of these hits, along with the percent inhibitions at 30 M are
shown in Fig. 1. Themolecules are divided into six groups depending on
their chemical properties. Group A represents electrophilic molecules
with a medium sized alkyl substituent. Based on our results at least two
of them are irreversible inhibitors of the TR-CoA interaction.
All hits shown in Fig. 1 were evaluated by performing a dose to the
response of inhibition study over a range of compound concentrations
of 0.024–30 M to allow the calculation of the IC50 values. Only two
compounds (Fig. 2B, L1 and L2) had IC50 values less than 10 M (C,
entries 1 and 2), with a clear saturation at a higher concentration (A).
These were designated validated hits. The remaining compounds were
all sufficiently weak in potency to call their validity into question. This
represents an overall hit rate of 0.00145%.
Both of the validated hits are -aminoketones. These compounds are
better known as Mannich bases, first synthesized in the 19th century
and systematically studied by Carl Mannich in the beginning of last
century (47). Several biological activities have been discovered for this
compound class including anticancer, antimicrobial, and cytotoxic
activities (48). These activities have been attributed to the liberation of
,-unsaturated ketones by internal elimination of the amino group.
Although this reaction proceeds very slowly under physiological pH in
water it has been reported that protein surfaces are able to catalyze this
reaction very efficiently (49). Such soft electrophiles, termed Michael
addition acceptors, can alkylate protein nucleophiles such as cysteine,
tyrosine, and serine. Because of the strong nucleophilicity of organic
sulfides, cysteine residues are the most reactive toward this class of
Michael acceptors.
To investigate the probability that a similar mechanism underlay
inhibition of coactivator binding to the TR LBD we tested the unsat-
urated ketone L3 (Fig. 2B). Interestingly, it showed a similar inhibitory
ability of the coactivator recruitment suggesting that indeed the liber-
ated unsaturated ketone L3 is the active species for compounds L1 and
L2 (Fig. 2C, entry 3). To determine whether the binding is based on the
TR-CoR Antagonists
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electrophilic nature of the molecule L3 and not on steric effects, a sat-
urated ketone L4 was tested. This compound exhibited no competitive
ability in the polarization assay (Fig. 2C, entry 4). Subsequentlywe inves-
tigated the importance of the alkyl substituent. Compound L5, with an
elongated alkyl chain and compound L6, with no substituent, both
failed to compete with SRC2-2 for binding to the TR LBD (Fig. 2C,
entries 5 and 6). Taken together, these results argue for a receptor tem-
plated covalent inactivation mechanism.
To ascertain some details of the deamination reaction presumably
producingL3, several compoundswith different alkyl nitrogen substitu-
ents that should possess different propensities for eliminationwere syn-
thesized and investigated in the coactivator binding assay with no sig-
nificant change in the IC50 values.4 Point mutations of the charged
amino acids Lys306 and Glu457 of the TR LBD diminish the binding of
SRC2 (24). This property prevented using thesemutants in the compet-
itive coactivator binding assay to investigate whether the deamination
reaction of L1 takes place at the coactivator binding pocket of TR LBD
or elsewhere on the TR protein surface.
A thyroid hormone binding assay in the presence of L3 was con-
ducted to rule out the possibility that the small molecule is competing
with T3, which would also result in the release of the labeled coactivator
in case of an antagonistic behavior (46). No competition of L3 with the
hormonal ligand was detected in a range of 0.1–10M L3 using [125I]T3
(Fig. 2D).
The probability of the formation of a covalent bond between L1 and
TR LBD was investigated by several independent methods. We syn-
thesized Bodipy-labeled compoundsL8 andL9 (Fig. 2E). To prove that
such acrylate analogs have similar activity as compound L3, we first
investigated the activity of a 4-alkyl-substituted aromatic acrylate L7
(Fig. 2B). This compound showed a similar activity in the competition
assay as the unsaturated ketone L3 (Fig. 2C, entry 7).
CompoundL8was incubated in different concentrations (10, 5, and 1
M) with TR LBD (5M) in the presence of T3 (20M). Separation by
a SDS-polyacrylamide gel showed a strong fluorescent band corre-
sponding to TR LBD-L8 (Fig. 2F, lanes 7–9). In contrast, incubation
with L9 resulted in no detectable band under the same conditions (Fig.
2F, lanes 4–6).
Mass spectroscopy is used extensively to detect modified biomol-
ecules like labeled proteins.Weobserved differentMS spectra for theL1
treated and untreated TR LBD (Fig. 2G). The difference of 200–250
m/z indicates that a covalent adduct is formed and that of one molecule
of TR LBD reacts with one molecule of compound L1. The exact
difference would be theoretically 217m/z, well within the experimental
error of the method.
The formation of a covalent bond between the L1 and TR LBD
implies that the binding is irreversible. In general irreversible inhibitors
show a significant time dependence, which varies with their concentra-
tion. Therefore a competition assaywithL1 in the presence of TR LBD
and fluorescent coactivator peptide was followed in time (Fig. 2H). At a
high concentration (50 M) L1 almost instantly inhibited binding of
SRC2-2 to the TR LBD coactivator site. A time dependence of inhibi-
tion over 4 h was discovered with concentrations of L1 between 25 and
1.5 M. At 0.33 M L1, no significant inhibition was observed. This
indicates that the inhibition is time dependent and requires a stoichio-
metric amount of L1, to the limits of accuracy of the determination of
protein concentration.4 L. A. Arnold, unpublished results.
FIGURE 1. Hit structures from HTS for inhibitors of the interaction of hTR and SRC2-2. Structures of hits are shown, grouped by chemotype, and annotated with the percent
inhibition of SRC2-2 binding at 30 M concentration of compound; A, electrophilic molecules with alkyl substituents; B, 7-nitrobenz-2-oxa-1,3-diazole derivatives; C, quinone and
coumarin derivatives; D, N-heterocycles; E, highly substituted pyrrolidone derivatives; F, stilbene derivatives.
TR-CoR Antagonists
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For L1 to inhibit coactivator binding to TR LBD there must be
accessible nucleophilic residues at the coactivator binding site. The LBD
of TR has seven cysteine residues. Most of them are exposed on the
surface of the protein. There are three cysteine residues near the coac-
tivator binding site. One is freely exposed at the surface (Cys298) and a
pair of two adjoining cysteine residues (Cys308 and Cys309) is buried
deeply in the binding pocket (Fig. 4A) (23). These cysteines are a unique
feature of the TR coactivator binding pocket relative to other NR. Based
upon our expectation of binding mode for the compounds, we hypoth-
esized that Cys309 was the most likely to be involved in the alkylation
reaction.
To test the hypothesis that Cys309 was forming the covalent adduct
with L1, we prepared a C309A TR LBDmutant. The mutant was fully
functional with respect to SRC2-2 binding in the presence of T3 meas-
ured by a direct binding assay (Kd 0.17M), in comparison to the wild
type TR LBD (Kd 0.44 M) (Fig. 3A). Using this mutant in a compe-
tition binding assay showed that the IC50 value of L1 was increased by
more than 50-fold suggesting that Cys309 plays a crucial role in the
inhibition of the coactivator recruitment of wild type TR by L1 (Fig.
3B). This hypothesis was supported by the fact that the labeling of TR
C309A, employing L8, was significantly less efficient in comparison to
the wild type (Fig. 2F, lanes 1–3).
The ability ofL1 to competewith intact coactivator SRC2, containing
all three SRC2 NR boxes, was tested using a semiquantitative glutathi-
one S-transferase assay (Fig. 3C). Control experiments indicated that
the SRC2 bound to full-length hTR in the presence of T3 (Fig. 3C, lane
4) and failed to bind in the absence of T3 (lane 3). This interaction was
blocked by L1 at concentrations between 200 and 7 M (Fig. 3C, lanes
5–8). At lower concentrations (2–0.7 M, Fig. 3C, lanes 9 and 10) no
inhibition was observed. The control experiment with compound L4
FIGURE2.Activities and structures of inhibitors.
A, competitive fluorescence polarization assay of
L2 in thepresenceof TR LBD (1M), T3 (1M), and
fluorescence labeled SRC2-2 peptide (10 nM). The
data were recorded after 4 h, and the IC50 is
extracted by fitting to the equation (y  min 
(max  min)/1  (x/Kd)Hill slope). B, small mole-
cule analogs of L1 synthesized to test mechanistic
hypotheses. C, summary of IC50 values of com-
pounds L1–L7 for TR and TR. Additionally the
ratio (selectivity) between TR LBD and TR LBD
are given for compound L1–L3. n.o., none
observed; n.d., none detected. D, competition
ligandbindingofL1 in thepresenceof 1nM[125I]T3
and full-lengthTR in agel filtrationbindingassay.
E, structure of labeled small molecules. F, fluores-
cent image of a 10% SDS-polyacrylamide gel
showing labeled small molecules covalent bound
toTR. Lanes 1–3, TRC309AandL8;4–6, TRand
L9; 7–9, TR and L8. G, matrix-assisted laser des-
orption ionization-mass spectrometry spectra of
untreated TR LBD and TR LBD treated with L1.
H, time dependence of inhibition of TR LBD coac-
tivator binding by L1 at different concentrations;
competitive fluorescence polarization assay was
followed over time.
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showed no inhibition at 200 M (Fig. 3C, lane 10). Thus, the inhibition
of interaction of full-length hTR and SRC2 by L1 exhibited dose
dependence, similar to the peptide binding studies described above.
The specificity of L1 inhibition of SRC2 binding was examined with
respect to both TR isoforms, TR and TR. Both isoforms were used
under the same conditions in a competition polarization assay. L1 com-
petes with SRC2 for binding to TRwith 12-fold lower apparent affinity
giving an IC50 of 24 M (Fig. 2C, entry 1). In the absence of T3 no SRC2
is recruited (Fig. 3B). ForL3 this differencewas even higher with 50-fold
decrease in affinity for TR (Fig. 2C, entry 3). Surprisingly L2 showed
similar affinities for both TR and TR, 2.6 and 2.1 M, respectively
(Fig. 2C, entry 2). As expected compounds L4, L5, and L6 showed no
binding to either isoform (Fig. 2C, entries 4–6).
To examine the influence of L1–L4 on transcriptional transactiva-
tion of a consensus thyroid response element, U2OS cells were cotrans-
fected with an expression vector TR1 and a thyroid response element-
driven luciferase reporter plasmid. After incubation for 18 h the
luciferase activity was determined for cells exposed to a fixed concen-
tration of T3 and different concentrations of compounds L1–L4 (Fig.
3D). The compounds L1–L3 showed full inhibition of transcription at
17 M. L4, used as a control, had almost no influence on the luciferase
activity in comparison to Me2SO alone. Minor inhibition of transcrip-
tion was observed at 4 M applying L1 and L2. L3 in contrast fully
suppressed transcription at concentration of 4 M and had minor
effects at 1 M.
At the concentrationsmeasured, the inhibition of transcription using
an expression vector TR C309A was similar for L1 and L2 in compar-
ison to the wild type TR (Fig. 3E). Major differences were observed for
L3 showing no inhibition at 1 M and only moderate potency at 4 M.
The viability of the cells was monitored with no significant cell death
taking place in any experiment at these concentrations.
DISCUSSION
A HTS of small molecules was successfully applied to find a hit that
led to the first cell activemodulators of nuclear hormone receptor coac-
tivator interactions. The screen was based on the ability of liganded TR
to recruit coregulator proteins capable of enhancing transcriptional reg-
ulation. We evaluated small molecules capable of inhibiting this pro-
tein-protein interaction by using fluorescence polarization with a pep-
tide probe representing the coregulator. During the initial screen we
identified 27 hit compounds showing an inhibition of more than 50% at
a concentration of 30M.The study of the dose response of inhibition of
these 27 compounds revealed two validated hits with an IC50 value of
less then 10 M. The overall hit rate of 0.00145% is unusually low for a
target-based HTS campaign. We hypothesize that this is because of the
absence of molecules with the correct chemotypes in a library whose
construction was biased toward current philosophy of “drug-like” char-
acter for enzymatic and cell surface receptor targets.
The two validated hit compounds L1 and L2, with IC50 values of 2.0
and 2.1 M, respectively, are -aminoketones. The biological activities
FIGURE3.Detailedmechanistic studies of inhib-
itors. A, direct binding assay of labeled SRC2-2
peptide to hTR LBD, hTR LBD, and hTR LBD
(C309A). The protein was serially diluted and
treatedwith 1M ligand T3 and 0.01M of fluores-
cent SRC2-2. The binding was measured after 30
min using fluorescence polarization. The Kd values
were obtained by fitting data to the following
equation (y  min  (max  min)/1  (x/Kd)Hill
slope). ●, TR LBD 0.17 M; Œ, TR LBD 0.46
M;f, TR LBD (C309A) 0.17M. B, competition
polarization assaywith labeled SRC2-2 peptide (10
nM), L1, and TR (1 M). L1 was serially diluted and
equilibrated with all components for 4 h prior to
analysis.●, TR LBD, no T3;Œ, TR LBDwith T3;,
TR LBD with T3; f, TR LBD (C309A) with T3. C,
autoradiogram of 10% SDS-polyacrylamide gel
showing products of in vitro binding reactions
between 35S-labeled SRC2 and GST fusion to full-
length TR. Lane 1, 10% input labeled SRC2; 2, GST
control; 3, no T3 hormone, 35S-labeled SRC2 bind-
ing is ligand-dependent; 4, no L1 inhibitor, maxi-
mal binding of 35S-labeled SRC2 to hTRb in the
presence of T3 (10 M); 5–10, different concentra-
tions of L1 in the presence of T3; 11, L4, no inhibi-
tion. D, inhibition of expression of a thyroid
response element-driven luciferase reporter
enzyme by L1–L4 at different concentrations in
the presence of a constant, fully inducing, concen-
tration of T3. U2OS cells were transfected with a
TR expression vector. The data are normalized to
basal expression (treatment with equal amounts
of Me2SO, but no T3) and fully induced expression
(treatment with equal amounts of Me2SO and T3).
E, inhibition of expression of a thyroid response
element-driven luciferase reporter enzyme by
L1–L4 at different concentrations in the presence
of a constant, fully inducing, concentration of T3.
U2OS cells were cotransfected with a TR C309A
expression vector. The data are normalized to
basal expression (treatment with equal amounts
of Me2SO, but no T3) and fully induced expression
(treatment with equal amounts of Me2SO and T3).
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of this class of compounds have been attributed to the fact that they can
liberate a corresponding unsaturated ketone capable of alkylating bio-
logical nucleophiles. A binding study with the corresponding unsatur-
ated ketone L3 showed an IC50 value of 0.9M. This result suggests that
the unsaturated ketone is the active species. To exclude the possibility
that steric properties of L3 are important for inhibition we tested satu-
rated compound L4. This compound was not able to inhibit the TR-
CoA binding.
We hypothesize that the deamination reaction producing the active
L3 in situ is catalyzed on the protein surface because of the unlikelihood
of an intramolecular mechanism at physiological pH. The small varia-
tion of IC50 values based on aminoketones with different alkyl nitrogen
substituents suggests a hydrophobic and fairly rigid catalytic site. How-
ever, direct investigation of the most likely catalytic residues of the TR
coactivator binding domain is prevented because these residues are nec-
essary for binding of the coactivator.
The electrophilic functionality of the active inhibitor species L3 has
been found to be an essential property of the TR antagonists suggesting
that the inhibition is based on the alkylation of nucleophilic residues
forming the TR-CoA interface. Binding studies with compounds L5
and L6 showed no inhibition, concluding that a medium-sized hydro-
phobic group at the 4 position of the aromatic -aminoketones is nec-
essary for interaction. Taken together, these studies strongly imply that
the active species of inhibitors are actually ,-unsaturated ketones
acting as direct alkylators of nucleophilic residues on the surface of the
thyroid receptor. This is supported by the fact that the natural ligand T3
is not released by the addition of L1, which implies that the conforma-
tion of TR is not altered in the presence of L1.
Covalent inhibitors have several unique properties. 1) They produce
an adduct with the target that has increased molecular weight. This
feature can be used to permanently label the corresponding binding
partner; 2) they require stoichiometric, but not largely superstoichio-
metric amounts of inhibitor for full activity, and 3) they exhibit strong
time dependence when acting in modest excess relative to the target
concentration. After the treatment of TR LBDwithL1we could detect
a new species with a 200–250m/z higher mass. We assigned this mass
to TR-L1 proving that TR is selectively alkylated by one equivalent of
L1. In addition we followed the inhibition of TR-CoA by L1 in time. A
significant time dependence of inhibition was found between L1 con-
centrations of 25 and 1.5 M when interacted with TR at a concentra-
tion of 1 M. The time dependence altered with the L1 concentration
suggesting an irreversible inhibition. A covalent complex was formed
when TRwas treated with fluorescently labeled analog L8, in contrast
to the inactive compound L9, lacking the electrophilic properties of L8,
which did not. In summary, the detection of the mono-alkylated TR,
its time-dependent formation, and the fact that TR could be covalently
labeled with a fluorescent inhibitor supports the postulated mechanism
that L1 forms the unsaturated ketone L3, alkylating irreversibly one of
the residues of TR LBD.
Based upon the expected chemical reactivity of L1, as predicted by
frontier molecular orbital theory, we would expect that L1 is most likely
to react with a solvent-exposed cysteine residue. The fact that we
observe a single alkylation event is exceptional because there are seven
cysteine residues present in TR LBD. Most of cysteine residues are
exposed to the surface of the protein. We hypothesized that the selec-
tivity might be driven by a preassociation event that positions the anti-
bonding orbital of the electrophile L1 near a nucleophilic cysteine. The
coactivator binding site has three cysteine residues (Fig. 4, Cys308,
Cys309, and Cys298). Of these, Cys309 seemed most likely to be reacting
with L1 based upon our expected mode of binding. To support this
hypothesis three independent experiments were carried out in systems
where cysteine residueCys309was replaced by an alanine: 1) competitive
coactivator binding studies using TR C309A revealed that L1 had a
50-fold reduced IC50 value in comparison with the wild type TR; 2)
direct labeling of TR C309A using L8 was less efficient in comparison
with the wild type; and 3) inhibition of transfection by L3 using U2OS
cells cotransfected by a TR C309A expression vector was significantly
reduced in comparison with the wild type. Although a direct compari-
sonwithC308A andC298A clones ismissing, we think that Cys309 is the
most likely target for L1. Cys309 is exposed in a defined hydrophobic
pocket capable of activation through nearby charged residues. The res-
idues forming the coactivator binding surface of TR and TR LBD are
identical (Fig. 4). Although crystal structures of the binding pockets of
the two isoforms of TR (TR LBD and TR LBD) are very similar, there
are distinct differences in the region immediately surrounding the
pocket.We think that these differences in the hydrophobic relief are the
reason for the significant differences in IC50 values for L1 and L3 for
TR and TR LBD. The decrease in affinity for TRwas 12-fold for L1
and 50-fold for L3. On the other hand, L2 showed the same affinity for
both isoforms. This selectivity is very important for future studies tar-
geting specific tissues with differently expressed levels of TR and TR.
The ability to inhibit a protein peptide interaction does not guarantee
that the same inhibitor will block the interaction of the full-length pro-
teins. In this case, L1 fully inhibited the interaction of full-length SRC2,
containing three NR boxes, and full-length TR. A concentration of 7
M L1 was sufficient for blocking this receptor coactivator interaction.
The fact that the potency of L1 in this semiquantitative glutathione
S-transferase assay matched that in the protein-peptide interaction
increased the likelihood that L1 would block this interaction between
the full-length transcription factors in a cellular environment.
FIGURE 4. Surface display of TR coactivator
binding pocket. A, TR; B, TR. The TR LBD coac-
tivatorbinding site is representedbya solid surface
indicating in gray the hydrophobic residues, in
blue the positively charged residues, in red the
negatively charged residues, and in yellow the cys-
teines. The thyroid receptor AF-2 transactivation
function is a surface exposed hydrophobic cleft
comprised of residues from helices 3, 5, and 12.
Some of these residues important for coactivator
binding are labeled in both TR and TR. Both are
depicted in identical orientation.
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A reporter gene transfection assay, carried out in cultured U2OS
cells, showed indeed that compoundsL1,L2, andL3were able to reduce
transcriptional activation to basal levels. L3 showed highly increased
potency in comparison to L1 and L2with almost full inhibition of tran-
scription at 4 M. We concluded that L3 can penetrate the cell mem-
brane and is transported to the nucleus. Furthermore it can inhibit
coregulator recruitment and has a direct impact on the transcriptional
activity of TR.
In summary, we report that small molecules are able to inhibit the
interaction between the liganded thyroid hormone receptor and its
coactivator SRC2. To our knowledge this is the first irreversible inhibi-
tor of the nuclear receptor coregulator binding that has been reported.
Molecules like L1 are a new class of TR antagonist, active in the pres-
ence of T3 but silencing its hormone-induced signaling. They open the
door to understand the coupling ofmultiple thyroid hormone-regulated
signaling events and the potential for treatment of hyperthyroidism
using approaches that do not affect thyroid hormone levels. Com-
pounds L1 and L3 exhibit exceptional TR selectivities making them
potentially useful for the study of tissue selective thyroid activities. We
are currently investigating the effects of these compounds in cell-based
assays and in vivo studies.
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